Tonix Pharmaceuticals Reports Q2 Revenue Surge as TONMYA Sales Reach $11 Million

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has reported second-quarter 2026 net product revenue of approximately $13.5 million, a substantial increase from $2 million in the same period last year. The growth was driven by approximately $11 million in net sales of TONMYA, the company's newly approved treatment for fibromyalgia. This marks a critical milestone for Tonix as it transitions from a development-stage biotech to a commercial-stage company with a flagship product gaining market traction.

TONMYA, which is the first new treatment for fibromyalgia in over 15 years, recorded 12,592 total prescriptions during the quarter, a 100% sequential increase. New patient prescriptions grew by 36%, while refills surged by 207%, indicating strong patient adherence and growing physician adoption. The drug's market access is expanding, with coverage representing approximately 136 million lives across commercial, managed Medicare, and Medicaid channels. This coverage is expected to reach approximately 145 million lives when a managed Medicare agreement takes effect on January 1, 2027, potentially boosting sales further.

The company is also making progress in its clinical pipeline. Tonix has enrolled the first patient in the potentially pivotal Phase 2 HORIZON study of TNX-102 SL for major depressive disorder (MDD). This study aims to evaluate the efficacy and safety of TONMYA in a new indication, which could significantly expand its market potential. Additionally, Tonix is preparing to begin an adaptive Phase 2 field study of TNX-4800 for Lyme disease prevention in the first quarter of 2027, pending final FDA review and agreement on the protocol. This program targets a high unmet medical need, as current prevention methods are limited.

Financially, Tonix ended the quarter with approximately $176.2 million in cash and cash equivalents. The company stated that its resources, together with third-quarter equity proceeds to date, are expected to fund planned operations and capital expenditures into early second-quarter 2027. This financial runway provides Tonix with the stability to continue commercializing TONMYA and advancing its pipeline without immediate funding concerns.

The strong performance of TONMYA is particularly important given the competitive landscape in fibromyalgia treatment. Historically, the condition has been difficult to manage, and approved therapies have had limited efficacy or tolerability issues. TONMYA offers a novel sublingual formulation of cyclobenzaprine, which may provide rapid absorption and potentially better tolerability. The 207% increase in refills suggests that patients are experiencing benefits and continuing treatment, a positive sign for long-term commercial success.

Tonix's focus on CNS and immunology addresses areas of high unmet medical need. In addition to TONMYA, the company's commercial portfolio includes acute migraine products Zembrace SymTouch and Tosymra. The pipeline includes TNX-2900 for Prader-Willi syndrome, a rare disease, and TNX-1500, a third-generation CD40 ligand inhibitor for prevention of kidney transplant rejection. These programs diversify Tonix's risk and offer multiple catalysts for future growth.

The implications of this earnings report are significant for investors and patients alike. For investors, the revenue surge demonstrates that Tonix can execute commercially, reducing the risk associated with a pure R&D play. For patients, TONMYA's growing adoption means a new treatment option is becoming more accessible, potentially improving quality of life for those suffering from fibromyalgia. The upcoming clinical data readouts for MDD and Lyme disease prevention could further expand the company's addressable market and solidify its position in the biotech sector.